BioCryst price target lowered to $25 from $27 at Citizens JMP

Citizens JMP analyst Jonathan Wolleben lowered the firm’s price target on BioCryst (BCRX) to $25 from $27 and keeps an Outperform rating on the shares following the Q3 earnings report. The firm likes the continued positive trajectory of Orladeyo sales fueled by a growing prescriber base, consistent high patient retention, and strong reimbursement dynamics, the analyst tells investors in a research note. BioCryst is well-positioned for growth, with Orladeyo sales continuing to move higher, pipeline expansion with the strategic addition of navenibart, and potentially de-risking Netherton syndrome data on the horizon, the firm states.